Nova Mentis Life Science Corp. (NOVA.CN)
CAD 0.01
(N/A%)
CAD 0.01
(N/A%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.2 Million CAD | -2.68% |
| 2022 | -1.17 Million CAD | 62.06% |
| 2021 | -3.08 Million CAD | -115.69% |
| 2020 | 19.66 Million CAD | 1857.1% |
| 2019 | -1.11 Million CAD | 68.57% |
| 2018 | -3.56 Million CAD | -97.87% |
| 2017 | -1.79 Million CAD | 8.24% |
| 2016 | -1.96 Million CAD | -178.41% |
| 2015 | -704.54 Thousand CAD | -43.44% |
| 2014 | -491.18 Thousand CAD | -160.07% |
| 2013 | -188.86 Thousand CAD | 71.37% |
| 2012 | -659.68 Thousand CAD | 33.16% |
| 2011 | -986.92 Thousand CAD | -41.25% |
| 2010 | -698.69 Thousand CAD | 62.39% |
| 2009 | -1.85 Million CAD | -146.29% |
| 2008 | -754.31 Thousand CAD | -22.81% |
| 2007 | -614.19 Thousand CAD | -503.79% |
| 2006 | -101.72 Thousand CAD | -63.44% |
| 2005 | -62.24 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -90.75 Thousand CAD | 42.6% |
| 2024 Q1 | -145.56 Thousand CAD | 30.91% |
| 2023 Q2 | -302.79 Thousand CAD | 42.65% |
| 2023 Q1 | -528 Thousand CAD | -256.22% |
| 2023 Q4 | -210.67 Thousand CAD | -10.48% |
| 2023 Q3 | -190.69 Thousand CAD | 37.02% |
| 2023 FY | -1.23 Million CAD | -5.23% |
| 2022 Q4 | 337.98 Thousand CAD | 174.62% |
| 2022 FY | -1.17 Million CAD | 62.06% |
| 2022 Q1 | -662.11 Thousand CAD | -339.8% |
| 2022 Q2 | -393.78 Thousand CAD | 40.53% |
| 2022 Q3 | -452.97 Thousand CAD | -15.03% |
| 2021 Q4 | -150.55 Thousand CAD | 89.49% |
| 2021 FY | -3.08 Million CAD | -115.69% |
| 2021 Q3 | -1.43 Million CAD | -237.05% |
| 2021 Q2 | -424.97 Thousand CAD | 31.17% |
| 2021 Q1 | -617.44 Thousand CAD | 41.67% |
| 2020 Q4 | -1.05 Million CAD | -119.62% |
| 2020 Q1 | -140.13 Thousand CAD | -4.07% |
| 2020 FY | 19.66 Million CAD | 1857.1% |
| 2020 Q2 | -120.76 Thousand CAD | 13.82% |
| 2020 Q3 | -482.01 Thousand CAD | -299.12% |
| 2019 Q3 | -391.47 Thousand CAD | -8.28% |
| 2019 Q2 | -361.52 Thousand CAD | -8.08% |
| 2019 Q1 | -334.49 Thousand CAD | 33.89% |
| 2019 Q4 | -134.65 Thousand CAD | 65.6% |
| 2019 FY | -1.11 Million CAD | 68.57% |
| 2018 Q2 | -232.68 Thousand CAD | 88.89% |
| 2018 Q3 | -710.08 Thousand CAD | -205.17% |
| 2018 FY | -3.56 Million CAD | -97.87% |
| 2018 Q1 | -2.09 Million CAD | -162.84% |
| 2018 Q4 | -506 Thousand CAD | 28.74% |
| 2017 Q3 | -402.13 Thousand CAD | -20.12% |
| 2017 FY | -1.79 Million CAD | 8.24% |
| 2017 Q2 | -334.78 Thousand CAD | -25.77% |
| 2017 Q1 | -266.18 Thousand CAD | 83.28% |
| 2017 Q4 | -796.62 Thousand CAD | -98.1% |
| 2016 Q3 | -194.05 Thousand CAD | -114.01% |
| 2016 Q1 | -85.19 Thousand CAD | 64.39% |
| 2016 FY | -1.96 Million CAD | -178.41% |
| 2016 Q2 | -90.67 Thousand CAD | -6.43% |
| 2016 Q4 | -1.59 Million CAD | -720.22% |
| 2015 FY | -704.54 Thousand CAD | -43.44% |
| 2015 Q1 | -169.11 Thousand CAD | -12.9% |
| 2015 Q2 | -115.74 Thousand CAD | 31.56% |
| 2015 Q3 | -180.43 Thousand CAD | -55.89% |
| 2015 Q4 | -239.25 Thousand CAD | -32.6% |
| 2014 Q1 | -72.51 Thousand CAD | -1223.33% |
| 2014 Q4 | -149.78 Thousand CAD | -13.9% |
| 2014 FY | -491.18 Thousand CAD | -160.07% |
| 2014 Q3 | -131.5 Thousand CAD | 4.27% |
| 2014 Q2 | -137.37 Thousand CAD | -89.46% |
| 2013 Q1 | -58.05 Thousand CAD | 60.93% |
| 2013 FY | -188.86 Thousand CAD | 71.37% |
| 2013 Q2 | -46.44 Thousand CAD | 20.01% |
| 2013 Q4 | 6455.00 CAD | 107.11% |
| 2013 Q3 | -90.82 Thousand CAD | -95.57% |
| 2012 Q1 | -171.01 Thousand CAD | 47.28% |
| 2012 FY | -659.68 Thousand CAD | 33.16% |
| 2012 Q3 | -211.27 Thousand CAD | -63.82% |
| 2012 Q4 | -148.6 Thousand CAD | 29.66% |
| 2012 Q2 | -128.96 Thousand CAD | 24.59% |
| 2011 Q2 | -331.79 Thousand CAD | -63.46% |
| 2011 Q1 | -202.97 Thousand CAD | -40.31% |
| 2011 Q3 | -213.95 Thousand CAD | 35.52% |
| 2011 FY | -986.92 Thousand CAD | -41.25% |
| 2011 Q4 | -324.4 Thousand CAD | -51.62% |
| 2010 Q3 | -149.64 Thousand CAD | 9.78% |
| 2010 Q1 | -238.51 Thousand CAD | 40.11% |
| 2010 Q4 | -144.65 Thousand CAD | 3.33% |
| 2010 Q2 | -165.87 Thousand CAD | 30.46% |
| 2010 FY | -698.69 Thousand CAD | 62.39% |
| 2009 Q4 | -398.24 Thousand CAD | 13.41% |
| 2009 FY | -1.85 Million CAD | -146.29% |
| 2009 Q3 | -459.9 Thousand CAD | -22.17% |
| 2009 Q2 | -376.45 Thousand CAD | 37.92% |
| 2009 Q1 | -606.39 Thousand CAD | -215.76% |
| 2008 Q2 | -188.09 Thousand CAD | -265.2% |
| 2008 Q3 | -322.67 Thousand CAD | -71.55% |
| 2008 FY | -754.31 Thousand CAD | -22.81% |
| 2008 Q1 | -51.5 Thousand CAD | 83.48% |
| 2008 Q4 | -192.04 Thousand CAD | 40.48% |
| 2007 Q4 | -311.79 Thousand CAD | -205.82% |
| 2007 Q1 | -96.54 Thousand CAD | -78.92% |
| 2007 Q3 | -101.95 Thousand CAD | -7.64% |
| 2007 Q2 | -94.71 Thousand CAD | 1.89% |
| 2007 FY | -614.19 Thousand CAD | -503.79% |
| 2006 Q3 | -17.05 Thousand CAD | -13.23% |
| 2006 FY | -101.72 Thousand CAD | -63.44% |
| 2006 Q1 | 148.00 CAD | 0.0% |
| 2006 Q4 | -53.95 Thousand CAD | -216.39% |
| 2006 Q2 | -15.06 Thousand CAD | -10276.35% |
| 2005 FY | -62.24 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -5.01 Million CAD | 76.041% |
| Asep Medical Holdings Inc | -7.72 Million CAD | 84.429% |
| BetterLife Pharma Inc. | -3.24 Million CAD | 62.895% |
| BioVaxys Technology Corp. | -2.4 Million CAD | 49.958% |
| ChitogenX Inc. | -2.83 Million CAD | 57.516% |
| Rapid Dose Therapeutics Corp. | -3.73 Million CAD | 67.842% |
| Defence Therapeutics Inc. | -12.65 Million CAD | 90.5% |
| Entheon Biomedical Corp. | -313.99 Thousand CAD | -282.908% |
| Gemina Laboratories Ltd. | -5.08 Million CAD | 76.36% |
| Glow Lifetech Corp. | -1.64 Million CAD | 26.81% |
| Lexston Life Sciences Corp. | -674.71 Thousand CAD | -78.193% |
| Pharmala Biotech Holdings Inc. | -762.95 Thousand CAD | -57.586% |
| Doseology Sciences Inc. | -377.63 Thousand CAD | -218.378% |
| MYND Life Sciences Inc. | -1.8 Million CAD | 33.493% |
| PharmaTher Holdings Ltd. | -3.04 Million CAD | 60.504% |
| PreveCeutical Medical Inc. | -963.12 Thousand CAD | -24.833% |
| Telescope Innovations Corp. | -5.76 Million CAD | 79.151% |